06/01/2021 | Press release | Distributed by Public on 05/31/2021 23:21
IBA initiates global DynamicARC® Consortium for the roll-out of Proton Arc Therapy
Louvain-la-Neuve, Belgium, June 1, 2021 - IBA (Ion Beam Applications S.A., EURONEXT), the world s leading provider of proton therapy solutions, has highlighted its commitment to shaping the future of proton therapy by initiating a global DynamicARC® Consortium (DAC), in collaboration with leading clinical centers.
The objective of the consortium is to prepare for the clinical roll out of the DynamicARC® treatment modality within the proton therapy community using the Proteus® platform. Specifically, the DAC members will ensure that the treatment modality reaches its full potential in terms of dose conformality and patient throughput.
Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the 2021 American Society of Clinical Oncology Annual Meeting
News provided by
Share this article
Share this article
NEWTON, Mass., May 19, 2021 /PRNewswire/ Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that sixteen abstracts have been selected for virtual presentation, including one oral presentation, at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 4-8, 2021.
Key abstracts to be presented at the meeting will feature clinical data for XPOVIO® (selinexor), the Company s first in class, oral Selective Inhibitor of Nuclear Export (SINE) compound, including: (i) multiple new subgroup analyses from the pivotal Phase 3 BOSTON study, including data results evaluating XPOVIO treatment for patients over the age of 65 years old and patients with RAS-mutated multiple myeloma; (ii